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failed to prevent AIP but prevented early pancreatic tissue damage. Administration of corticosteroids
reduced pancreatitis but did not affect production of autoantibodies, such as anti-pancreatic secretory
trypsin inhibitor in Ela1-LTab mice. In contrast, inhibition of LT￿R signaling reduced chemokine ex-
pression, renal immune-complex deposition, and features of AIP in Ela1-LTab mice. CONCLUSIONS::
Overexpression of LT ￿ ￿specifically in acinar cells of mice causes features of AIP. Reagents that neutralize
LT ￿ R ligands might be used to treat patients with AIP.
DOI: 10.1053/j.gastro.2012.07.112
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-64333
Accepted Version
Originally published at:
Seleznik, Gitta M; Reding, Theresia; Romrig, Franziska; Saito, Yasuyuki; Mildner, Alexander; Segerer,
Stephan; Sun, Li-Kang; Regenass, Stephan; Lech, Maciej; Anders, Hans-Joachim; McHugh, Donal; Ku-
magi, Teru; Hiasa, Yoichi; Lackner, Carolin; Haybaeck, Johannes; Angst, Eliane; Perren, Aurel; Balmer,
Maria Luisa; Slack, Emma; Macpherson, Andrew; Manz, Markus; Weber, Achim; Browning, Jeffrey
L; Arkan, Melek Canan; Rülicke, Thomas; Aguzzi, Adriano; Prinz, Marco; Graf, Rolf; Heikenwalder,
Mathias (2012). Lymphotoxin ￿ receptor signaling promotes development of autoimmune pancreatitis.
Gastroenterology, 143(5):1361-1374. DOI: 10.1053/j.gastro.2012.07.112
2
 
Accepted Manuscript 
Lymphotoxin β Receptor Signaling Promotes Development of 
Autoimmune Pancreatitis 
Gitta M. Seleznik, Theresia Reding, Franziska Romrig, Yasuyuki 
Saito, Alexander Mildner, Stephan Segerer, Li-Kang Sun, Stephan 
Regenass, Maciej Lech, Hans-Joachim Anders, Donal McHugh, 
Teru Kumagi, Yoichi Hiasa, Carolin Lackner, Johannes Haybaeck, Eliane Angst, Aurel 
Perren, Maria Luisa Balmer, Emma Slack, Andrew MacPherson, Markus Manz, Achim 
Weber, Jeffrey L. Browning, Melek Canan Arkan, Thomas Rülicke, Adriano Aguzzi, 
Marco Prinz, Rolf Graf, Mathias Heikenwalder 
PII: S0016-5085(12)01153-5 
DOI: 10.1053/j.gastro.2012.07.112 
Reference: YGAST 57919 
To appear in: Gastroenterology 
Received date: 25 April 2012 
Revised date: 9 July 2012 
Accepted date: 28 July 2012 
 
Please cite this article as: Seleznik, G.M., Reding, T., Romrig, F., Saito, Y., Mildner, A., 
Segerer, S., Sun, L.K., Regenass, S., Lech, M., Anders, H.J., McHugh, D., Kumagi, T., 
Hiasa, Y., Lackner, C., Haybaeck, J., Angst, E., Perren, A., Balmer, M.L., Slack, E., 
MacPherson, A., Manz, M., Weber, A., Browning, J.L., Arkan, M.C., Rülicke, T., 
Aguzzi, A., Prinz, M., Graf, R., Heikenwalder, M., Lymphotoxin β Receptor Signaling 
Promotes Development of Autoimmune Pancreatitis, Gastroenterology (2012), doi: 
10.1053/j.gastro.2012.07.112. 
 
This is a PDF file of an unedited manuscript that has been accepted for publication. As a 
service to our customers we are providing this early version of the manuscript. The 
manuscript will undergo copyediting, typesetting, and review of the resulting proof 
before it is published in its final form. Please note that during the production process 
errors may be discovered which could affect the content, and all legal disclaimers that 
apply to the journal pertain. 
 
 
All studies published in Gastroenterology are embargoed until 3PM ET of the day they 
are published as corrected proofs on-line. Studies cannot be publicized as accepted 
manuscripts or uncorrected proofs. 
1 
 
Lymphotoxin β Receptor Signaling Promotes Development of Autoimmune 
Pancreatitis 
 
Gitta M. Seleznik1, Theresia Reding2, Franziska Romrig3, Yasuyuki Saito4, Alexander 
Mildner5, Stephan Segerer6, Li-Kang Sun2, Stephan Regenass7, Maciej Lech8, Hans-
Joachim Anders8, Donal McHugh1, Teru Kumagi9,Yoichi Hiasa9,Carolin Lackner10, 
Johannes Haybaeck10, Eliane Angst11, Aurel Perren11, Maria Luisa Balmer12, Emma 
Slack12, Andrew MacPherson12, Markus Manz4, Achim Weber13, Jeffrey L. 
Browning14, Melek Canan Arkan3, Thomas Rülicke15, Adriano Aguzzi1, Marco 
Prinz4,Rolf Graf2,* and Mathias Heikenwalder1,16,*. 
*contributed equally 
 
1Institute of Neuropathology, Schmelzbergstrasse 12, 8091, Zurich, Switzerland. 
2Department of Surgery, Swiss Hepato-Pancreato-Biliary Center, University Hospital Zurich, 
Switzerland. 
3Second Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675 
Munich, Germany. 
4 Division of Haematology, University Hospital Zurich. 
5 Department of Neuropathology, University of Freiburg, Freiburg, Germany. 
6 Division of Nephrology, University Hospital Zurich, Zurich, Switzerland. 
7 Division of Clinical Immunology, University Hospital Zurich, Switzerland. 
8Medizinische Klinik IV, Klinikum der Universität München, Campus Innenstadt, Munich, Germany. 
9Gastroenterology and MetabologyEhime University, Graduate School of Medicine 
Shitsukawa To-on, Ehime 791-0295, JAPAN 
10Institute of Pathology, Medical University Graz, Austria. 
Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Austria. 
11Departments of Visceral Surgery and Pathology, Inselspital, University of Bern, Switzerland. 
12Department of Gastroenterology, BHH D117,Inselspital, University of Bern, Switzerland. 
13Institute of Clinical Pathology, Schmelzbergstrasse 12, 8091, Zurich, Switzerland. 
14Biogen-Idec, Department of Immunology, Cambridge, Massachusetts 02142, USA. 
15Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Austria. 
16Insitute of Virology, Technische Universität München (TUM)/ Helmholtz-Zentrum München, 
Germany.  
 
Corresponding authors: 
Mathias Heikenwälder Rolf Graf  
Department of Pathology Swiss Hepato-Pancreato-Biliary-Center 
Schmelzberstrasse 8 Rämistrasse 100   
University Hospital Zürich University Hospital Zürich 
Zürich, Switzerland Department for Visceral Surgery 
 Zürich, Switzerland   
E-Mail: mathias.heikenwaelder@usz.ch E-Mail: rolf.graf@usz.ch 
 
2 
 
Disclosure/Conflict of Interest 
Stephan Segerer receives benefits from ROCHE as a consultant.  Jeffrey Browning is an 
employee of Biogenidec and is involved with the development of LTBR-Ig. 
The remaining authors declare no conflicts of interest.  
 
Author contributions: GS designed and performed experiments, analyzed data and wrote 
the manuscript; TR, FR, YS, AM, SS, LS, SR, ML, DM, MB, ES, TR performed  experiments; 
TK, YH, CL, JH, EA, AP provided human material and participated in paper writing ; JB 
provided murine material and participated in paper writing, WA contributed to the 
pathological analysis of tissues and editing the manuscript, HA, AM, MM, MA, AA, MP 
participated in editing the manuscript and provided conceptual advice; RG and MH designed 
the study, analyzed the data and wrote the manuscript.  
 
Grant supports: This work was supported by a Helmholtz-Young investigator grant (M.H.), 
an ERC Starting grant (M.H), a SNF grant (R.G.; M.H.; St.S), a DFG grant (M.C.A.), the 
Amélie Waring Foundation Zurich (R.G., Th.R.) the Kurt und Senta Hermann and 
Oncosuisse foundation (A.W.; M.H.), an SFB-Transregio TR36 (M.H.) and the Austrian 
Federal Ministry of Science and Research GEN-AU grant ”Austromouse” TR. MP was 
supported by the FOR1336 of the German Research Council (DFG) and the Center of 
Chronic Immunodeficiency (CCI). H.J.A. and M.L. were supported by LE2621/2-1 and GRK 
1202 via the German Research Council (DFG). 
 
 
Abbreviations used in the paper: AIP, autoimmune pancreatitis; ANA, anti-nuclear 
antibodies; CP, chronic pancreatitis; FDC, follicular dendritic cells; HEV, high endothelial 
venules; LT, Lymphotoxin; LF, lactoferrin; PSTI, pancreatic secretory trypsin inhibitor; TLT, 
tertiary lymphoid tissue; TNF, tumor necrosis factor; Treg, regulatory T-cells;  
3 
 
Background & Aims: Little is known about the pathogenic mechanisms of autoimmune 
pancreatitis (AIP), an increasingly recognized, immune-mediated form of chronic pancreatitis. 
Current treatment options are limited and disease relapse is frequent. We investigated 
factors that contribute to development of AIP and new therapeutic strategies.  
 
Methods: We used quantitative PCR, immunohistochemical and ELISA analyses to measure 
expression of cytokines and chemokines in tissue and serum samples from patients with and 
without AIP. We created a mouse model of human AIP by overexpressing LTα and β 
specifically in acinar cells (Ela1-LTab mice). 
 
Results: mRNA levels of lymphotoxin (LT) α and β were increased in pancreatic tissues from 
patients with AIP, compared with controls, and expression of chemokines (CXCL13, CCL19, 
CCL21, CCL1 and BAFF) was increased in pancreatic and serum samples from patients. 
Upregulation of these factors was not affected by corticosteroid treatment. Acinar-specific 
overexpression of LTαβ (Ela1-LTαβ) in mice led to an autoimmune disorder with various 
features of AIP. Chronic inflammation developed only in the pancreas but was sufficient to 
cause systemic autoimmunity. Acinar-specific overexpression of LTαβ did not cause 
autoimmunity in mice without lymphocytes (Ela1-LTab/Rag1-/-); moreover lack of pro-
inflammatory monocytes (Ela1-LTab/Ccr2-/-) failed to prevent AIP but prevented early 
pancreatic tissue damage. Administration of corticosteroids reduced pancreatitis but did not 
affect production of autoantibodies, such as anti-pancreatic secretory trypsin inhibitor in Ela1-
LTab mice. In contrast, inhibition of LTβR signaling reduced chemokine expression, renal 
immune-complex deposition, and features of AIP in Ela1-LTab mice. 
 
Conclusions: Overexpression of LTαβ specifically in acinar cells of mice causes features of 
AIP. Reagents that neutralize LTβR ligands might be used to treat patients with AIP. 
 
Keywords: Tertiary lymphoid tissues; immune regulation; Regulatory T cell, TNF superfamily
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Introduction 
Chronic pancreatitis (CP) is an inflammatory disease of the exocrine pancreas with 
irreversible tissue damage resulting in severe exocrine and endocrine insufficiency [1]. 
Chronic destruction of acinar cells usually coincides with inflammation, metaplasia and 
fibrosis. Autoimmune pancreatitis (AIP) is a distinct form of CP with unknown aetiology, but 
with characteristic clinical, histological features [2]. 11-15% of all CP cases presumably 
develop in an autoimmune context [3]. Two types of AIP have been described: (1) Type 1 
AIP develops into a systemic IgG4-positive disease, with pancreatic lymphoplasmacytic 
inflammation, germinal center formation and vasculitis, (2) Fibro-inflammatory duct-centric 
type (type 2 AIP) with granulocyte epithelial lesions and pancreatic duct destruction without 
IgG4-positive cells or systemic involvement [4]. 
Elevated IgG4 levels are currently the most sensitive serum parameter for diagnosis [5]. 
However, about half of all AIP patients have normal serum IgG4 levels, and elevated IgG4 
levels were reported in non-autoimmune pancreatitis and pancreatic cancer [6]. Recently, B-
cell activating factor (BAFF) was identified as a novel serum marker for diagnosis and 
treatment response of AIP in combination with total serum IgG and IgG4 or anti-nuclear 
antibodies (ANA) [7].  
Auto-antibodies have been detected in human AIP against carbonic anhydrase II (anti-CA-II), 
lactoferrin (anti-LF) and trypsinogen [8]. Current studies revealed that approximately 40% of 
AIP patients suffer from extra-pancreatic manifestations involving liver, salivary glands, retro-
peritoneum or kidneys [9]. Thus, AIP is a systemic autoimmune disease, responding  to 
conventional steroid treatment [3]. However, relapses are frequent (~40%) and are 
associated with a more severe disease course [10]. Hence, novel therapeutic strategies and 
better understanding of the underlying disease mechanisms are needed.  
Major regulators of immunity under normal and pathological conditions include the cytokines 
LTα, LTβ and their receptor (LTβR), members of the tumor necrosis factor (TNF) 
superfamily. Under physiological conditions, activated immune cells express LT. Under 
pathological conditions, parenchymal cells - like hepatocytes - are also capable of expressing 
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LT [11]. LTβR-signaling serves pleiotropic functions including development of lymphoid 
organs [12] and control of lipid homeostasis [13]. LT is crucial for generation and 
maintenance of tertiary lymphoid tissues (TLTs), frequently arising during chronic 
inflammation [11] [14] [15] and in many autoimmune diseases (e.g. rheumatoid arthritis, 
Sjögren’s syndrome) [16,17]. TLTs upregulate LT, express chemokines, adhesion molecules 
and contain cells or structures depending on LTβR-signaling (e.g. follicular dendritic cells 
(FDC), high endothelial venules (HEVs)) [14,18-21]. Ectopic LT expression was previously 
investigated in transgenic animal models such as RIP-LTα [22], AlbLTαβ [11] and 
lckLTαβ [23]. Although these models display TLTs in the respective organs, they lack 
autoimmune disease. 
Human AIP tissue displayed strong up-regulation of LTαβ and target genes. Thus, we 
created transgenic mice expressing LT under the control of the acinar-cell specific elastase 
promoter (Tg(Ela1-LTa,b)) to test the potential role of LT in AIP pathology. We utilized 
Tg(Ela1-LTa,b) mice to investigate AIP disease mechanisms, and to explore novel 
therapeutic strategies for AIP. 
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Materials and Methods: 
Human samples: Human pancreas biopsies and serum samples were obtained from the 
University Hospitals Zurich and Bern, the University of Graz and Ehime University. All 
samples were registered in the respective biobanks and kept anonymous. The research 
project was authorized by the Ethics Committee ofthe Canton of Zurich (Ref. Nr.StV 26-
2005), local ethics committee Bern, Graz (Ref. Nr 20-492 ex 08/09), and the Ehime 
University Graduate School of Medicine (#1001003).The study followed the ethical 
guidelines of the Helsinki declaration.  
 
 
Antinuclear antibody (ANA) detection: Sera obtained from Tg(ELa1-Lta,b) and C57BL/6 
mice at the age of 6, 12 and 18 months were used to detect the presence of ANA using Hep2 
cells (Euroimmun Lübeck, Germany). The cells were incubated with 1:60 and 1:200 dilutions 
of each mouse serum sample in PBS, followed by incubation with FITC-conjugated 
polyclonal goat antibody to mouse IgG-H&L (Abcam, Cambridge, UK). The reaction was 
visualized using a LEICA DLMB immunofluorescence microscope (absorption, 485–520 nm; 
emission, 520–560 nm wavelengths) Staining intensity was determined visually by two 
independent experienced technicians of the diagnostic immunology laboratory.  
 
Statistical analyses and software: GraphpadPrism version 5 (LaJolla, Ca) was used to 
construct figures and diagrams. One-way ANOVA or unpaired t-tests and Mann-Whithey 
tests were used where appropriate. Differences were considered statistically significant if P< 
0.05 and marked with an asterisk*: P<0.05; **: P<0.01, ***: P<0.001. 
Additional methods are described in the supporting information.  
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Results 
 
Distinct expression patterns in non-AIP versus AIP patients  
We first analysed samples derived from inflammation-unaffected patients, patients with 
pancreatic inflammation, and AIP-patients (Supplementary Table 1A) by qPCR for the 
expression of cytokines and chemokines. Identical tissue specimens used for mRNA 
expression were pre-screened by H&E staining verifying respective pancreatic pathologies 
(Figure1A). Strong upregulation of LTα, LTβ, CXCL13, CCL19, CCL21, CCL17 and BAFF 
was found in AIP patients (Figure 1B, Supplementary Figure1A). IL17, which was recently 
proposed as crucial for autoimmune disease and TLT development [24] in non-lymphoid 
organs was  not significantly induced. In contrast, increase in CCL20, TNFα, CCL2, IL6, α-
SMA and IL17 transcripts was found in fibrotic, non-AIP pancreata compared to healthy 
controls or AIP patients (Figure 1B; Supplementary Figure 1B). 
 
LT expression on infiltrating lymphocytes and metaplastic acinar cells 
We next aimed at identifying cells expressing LT in pancreata of CP and AIP patients 
(Supplementary Table 1B). Immunohistochemistry of pancreatic tissues revealed strong 
LTβ protein expression on infiltrating lymphocytes and acinar cells in non-AIP patients with 
fibrotic pancreatitis and AIP patients compared to control tissues. In most cases, the latter 
underwent acinar-ductal-metaplasia (ADM) (Figure1C). No overt difference in pancreatic 
LTβ protein expression was observed in terms of distribution and amount of LTβ positive 
cells between type 1 (n=9) and type 2 AIP (n=7) cases. Double-staining with markers for T-
cells, B-cells and acinar-cells supported this finding (Supplementary Figure1C).  
 
Serum analysis of healthy individuals and AIP patients 
The observed cytokine, chemokine induction was detectable in serum of AIP patients (Figure 
1D; Supplementary Figure1D). Homeostatic chemokines (e.g. CXCL13) and pro-
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inflammatory cytokines (TNFα, IL6) were significantly elevated in sera of AIP patients 
compared to healthy individuals. We next investigated whether these chemokines are 
modulated upon corticosteroid treatment in AIP patients (n=10) (Supplementary Table1C). 
Corticosteroid treatment for 12 weeks failed to change the investigated cytokines and 
chemokines. Therefore, although corticosteroid-treatment strongly reduced some indicators 
of inflammation and immune activation (IgG, IgG4) (Supplementary Figure1E), important 
inflammatory mediators remained elevated, indicating a possible cause for disease re-
emergence. 
 
Generation and characterization of Tg(ELa1-Lta,b)mice 
Data presented above indicate a distinct signature in fibrotic pancreatitis and AIP. Strong LT 
upregulation and its focal expression on metaplastic acinar cells in AIP patients suggested a 
link between LT expression and AIP. Hence, we tested whether ectopic LT expression in the 
exocrine pancreas induces tissue damage and AIP in mice. Thus, double transgenic mice 
expressing LTα and LTβ (ELa1-Lta,b) in the pancreas under the control of the rat elastase 1 
promoter were generated (Supplementary Figure2A) [25].  
Tg(ELa1-Lta,b) mice showed elevated levels of amylase and lipase by the age of one month 
(Figure 2A), indicating tissue damage. Pancreas to body weight ratio was calculated in three, 
six and twelve month-old mice (Figure 2A). Pancreata were significantly smaller (30-40%) in 
Tg(ELa1-Lta,b) compared to non-transgenic littermates. Already after 8 weeks focal 
infiltrating immune cells accumulated in the pancreas, accompanied by ADM (Figure2A). 
Pancreatitis progressed over time, with strong influx of inflammatory cells and concomitant 
proliferation of acinar-cells with pronounced tissue damage at 12-22 months of age (Figure 
2B; Supplementary Figure4). After 6 months of age organized B- and T-cell zones - 
indicative of TLT formation - were found. Sporadic acinar-to-goblet cell metaplasia and 
vasculitis were observed; histo-pathological features commonly found in human CP 
(metaplasia) or AIP (vasculitis) (Figure 2C).  
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Chronic pancreatitis can lead to endocrine insufficiency; therefore, we tested whether Tg 
mice are diabetic. Even though Tg(ELa1-Lta,b) mice remained tolerant during an 
intraperitoneal glucose tolerance test (IPGTT, Figure 3E), they had to secrete ~ 2-3 fold more 
insulin than their littermates to support the same glucose clearance.  
 
Tg(ELa1-Lta,b) mice display a transcriptional signature reminiscent of human AIP 
Next, we investigated chemokine and cytokine expression in pancreata of three-and twelve-
month-old transgenic mice. Expression of endogenous Lta and Ltb transcripts increased over 
time. Similar to human AIP patients, induction of homeostatic chemokines (Cxcl13, Ccl19, 
Ccl21, Ccl17) was observed. Moreover, elevated expression of Ccl20, the adhesion molecule 
Vcam, the inflammatory chemokines Cxcl1, Cxcl10, Ccl2, the inflammatory cytokines Baff, 
Il6, Il1β, Il7 and Tnfα was detected on mRNA and protein level (Figure3A-B). This pattern 
resembles a progressive inflammatory response concomitant with the formation of a 
homeostatic environment favourable to TLT development. Similar to human AIP patients, 
serum protein levels for CXCL13 were elevated in transgenic mice (Figure3C). 
To define the immune cell populations in transgenic pancreata at the age of three and six 
months, we performed flow cytometry on isolated mononuclear cells. Consistent with the 
histological evaluation, a drastic increase in CD4+, CD8+, B220+CD11b+ cells in transgenic 
pancreata was found. In contrast, littermates displayed almost no detectable inflammatory 
cells (Figure3D and Supplementary Figure6B). 
In order to elucidate which proinflammatory signaling pathways could be of relevance for AIP 
development immunohistochemical analysis was performed for nuclear RelA/ RelB - to 
define activation of the canonical, non-canonical NF-κB signaling, and to analyse activation 
of Stat3 signaling (Supplementary Figure 6D). We identified RelB translocation mainly in 
acinar cells of Tg(Ela1-LTab) but not in C57BL/6 mice. In contrast, RelA translocation could 
not be detected in acinar or infiltrating immune cells. Stat3 phosphorylation was detected in 
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both acinar and inflammatory cells, indicating a possible involvement of Stat3 signaling in 
AIP pathogenesis in Tg(Ela1-LTab) mice. 
 
Germinal center formation and increased regulatory T-cells in Tg(ELa1-Lta,b) mice 
We further characterized the lymphocyte populations in Tg(ELa1-Lta,b) pancreata and in its 
draining lymph node (mesenteric LN) in more detail. A drastic increase in activation of 
memory and effector CD4+ and CD8+ T-cells in Tg(ELa1-Lta,b) pancreata was observed at 
the age of 12 months. Additionally, we found enhanced recruitment of regulatory T-cells (Treg) 
in Tg(ELa1-Lta,b) pancreata (Figure4A-C),which is also described in several autoimmune 
diseases [26], [27].  
Next, we evaluated the T-helper cell subsets (Th1/Th2/Th17) in pancreas, based on their 
distinct cytokine production profile (Figure4D). Strong upregulation of Ifnγ, Tnfα and the 
transcription factor T-bet in 12-month old Tg mice indicates the presence of predominantly 
Th1-type cells. Although the expression of Gata3 is known to control the development of Th2 
lineage, recently a stable Gata3+/T-bet+ cell subset was described [28]. Lymphotoxin-
expressing B cells were recently shown to regulate CXCR5-dependent Th2 response [29]. 
Correspondingly, cytokines secreted by Th2 cells in Tg mice such as Il4 and Il10 were also 
slightly upregulated. Th17 cytokines, Il17A, Il17F and some Th2 cytokines (Il5, Il13) were 
undetectable in pancreata of Tg(ELa1-Lta,b) mice (data not shown), which correlates with 
our analyses of human AIP pancreata. Of note, in peripheral blood of human AIP patients, 
Th1 cells but not Th17 cells are predominant over Th2-type cells [30]. 
By the age of three months transgenic pancreata contained HEVs (Figure4E). At later time 
points follicles developed into TLTs characterized by distinct T- and B-cell areas containing 
clusters of proliferating lymphocytes, germinal center B-cells, and FDC networks (Figure4F). 
 
Increased immunoglobulins and auto-antibodies in Tg(ELa1-Lta,b)  mice 
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We next investigated whether Tg mice display increased immunoglobulins and/or auto-
antibodies.  
Since IgG4 does not exist in mice, we analysed serum IgG, IgM and IgA levels in twelve-
month old Tg(ELa1-Lta,b) mice. We found significant increase in total IgG, IgG1, IgG2b, and 
IgM of Tg(ELa1-Lta,b) mice (Figure5A), which parallels the hyper-γ-globulinemia found in 
human AIP [30].  
The increased serum immunoglobulins and the presence of TLTs in the pancreas suggest 
that Tg(ELa1-Lta,b) mice developed an autoimmune phenotype. Indeed, ANA were present 
in sera of Tg(ELa1-Lta,b) mice with an incidence of ~66% at the age of twelve months 
(Figure5B and Supplementary Figure8). To assess the specificity of ANA, we measured 
plasma concentrations of anti-nucleosome and anti-dsDNA antibodies, which were both 
increased in twelve-month-old Tg(ELa1-Lta,b) mice. Rheumatic factor (RF) is elevated in 
sera of AIP patients [31], which was also observed in Tg(ELa1-Lta,b) mice along with anti-
Smith IgG, indicating systemic autoimmune disease (Figure5C). Thus, auto-antibodies, as 
well as indicators of systemic autoimmune disease are present in the sera of Tg(ELa1-
Lta,b) mice. 
We next investigated whether Tg(ELa1-Lta,b) mice developed auto-antibodies against 
pancreatic self-antigens, as observed in human AIP [30]. Autoantibodies against PSTI, LF 
and Lipase were significantly elevated in twelve-month-old Tg(ELa1-Lta,b) mice (Figure5D).  
 
Tg(ELa1-Lta,b) T-cells cause acute pancreatic damage in Rag1-/- mice 
To examine the immune cells contributing to pancreatic damage in AIP pathogenesis, we 
transferred C57BL/6 and Tg splenocytes into Rag1-/- recipients. 7 days post splenocyte 
transfer, Tg donor CD3+ cells, but not B220+ B-cells (data not shown) were found in 
pancreata of Rag1-/- recipient mice. Concomitantly, significant elevation of serum amylase 
levels was observed (Figure5E). In contrast, no changes were observed after adoptive 
transfer of C57BL/6 splenocytes. 
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Glomerulonephritis in Tg(ELa1-Lta,b) mice 
Transgenic mice developed glomerular lesions at the age of twelve months. The mesangial 
matrix of Tg(ELa1-Lta,b) kidneys was broadened, resulting in narrowed peripheral capillaries. 
Mesangial IgG deposits were demonstrated by light- and electron microscopy (Figure5F; 
Supplementary Figure8C). The increased accumulation of immune deposits and Mac-2+ 
macrophages in glomeruli correlated with age, resemble an immune-complex 
glomerulonephritis, observed also in some AIP patients. However, in Tg(ELa1-Lta,b) mice we 
could not observe pathological changes in livers, lungs, salivary – and lacrimal glands (data 
not shown).  
 
The role of monocytes and lymphocytes in the initiation and progression of AIP 
We next crossed Tg(ELa1-Lta,b) mice to mice lacking B- and T-lymphocytes (Rag1-/-) or pro-
inflammatory monocytes (Ccr2-/-) [32], [33] (Figure6A). 
Crossing to Rag1-/- mice resulted in early pancreatic injury, based on serum lipase levels 
(Figure6B) and ADM formation. Furthermore Tg(ELa1-Lta,b)xRag1-/- mice showed increased 
F4/80+ macrophage infiltration. On the contrary, lack of pro-inflammatory monocytes rescued 
the early onset of pancreatic tissue damage and prevented lipase elevation; however, 
modest lymphocytic infiltration was observed. This indicates that pro-inflammatory 
monocytes support the initiation of pancreatitis in transgenic mice. Altered transcriptional 
expression at 8 weeks corroborated this difference. Tg(ELa1-Lta,b)xCcr2-/- mice displayed 
increased homeostatic chemokines, while in the absence of B- and T-cells, genes involved in 
macrophage activation, e.g. Tnfα, Il6 and Ccl2 were significantly increased (Figure6C). 
Between three and six months, B- and T-cells also appear to contribute to pancreatic 
inflammation, as serum lipase levels show similarly reduced levels in both Tg(ELa1-
Lta,b)xRag1-/- and Tg(ELa1-Lta,b)xCcr2-/- mice (Figure6B). At twelve months, chronic tissue 
damage appeared to be driven by lymphocytes, as Tg(ELa1-Lta,b)xCcr2-/-  show organized T- 
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and B-cell infiltrates concomitant with significantly elevated serum lipase levels compared to 
Tg(ELa1-Lta,b)xRag1-/-mice. Twelve-month-old Tg(ELa1-Lta,b)xCcr2-/- mice displayed 
elevated anti-PSTI antibody levels (Supplementary Figure10) and immune deposits in 
kidneys (Figure6D). Thus, lack of pro-inflammatory monocytes protects from early pancreatic 
damage, but it does not affect the extent of AIP. From three months onwards, lack of 
lymphocytes resulted in reduced tissue damage and failed to induce AIP, suggesting that 
lymphocytes are directly involved in sustaining tissue damage and AIP in Tg(ELa1-Lta,b) 
mice.   
 
Corticosteroid treatment acts anti-inflammatory but not anti-autoimmune  
Four weeks of prednisolone treatment in twelve-month-old mice significantly reduced 
histological signs of inflammation and metaplasia (Figure7A-B). However, the systemic 
autoimmune reaction remained unaffected, with persistence of anti-PSTI antibodies and 
renal immune complexes (Figure7D-F). Severe side effects of steroid treatment and frequent 
relapses are well-documented in patients [10]. Therefore, we compared prednisolone 
treatment with inhibitors of the CD40L-CD40 or the LTα1β2-LTβR-signaling pathway (Figure7; 
Supplementary Figure11). Targeting the CD40 pathway did not result in amelioration of 
autoimmune pancreatitis in mice. However, LTβR-Ig (a soluble chimeric protein inhibiting 
LTβR-signaling) [34] abrogated pancreatic inflammation, ADM and significantly reduced 
expression of chemokines and cytokines compared to prednisolone treatment (Figure7). It 
led to a reduction of auto-antibodies and immune complex deposition in the glomeruli. This 
suggests that in Tg(ELa1-Lta,b) mice, prednisolone acts rather anti-inflammatory than anti-
autoimmune.   
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Discussion 
The underlying mechanisms inducing and maintaining AIP currently remain elusive. Here, we 
showed that patients suffering from AIP display high pancreatic LTαβ and chemokine 
expression in the inflammatory and fibrotic stages. Not only could we detect expression of LT 
on infiltrating lymphocytes, but also strong up-regulation on acinar cells that underwent 
metaplasia.  While some aspects of expression was similar in all patients, AIP and severely 
fibrotic pancreata displayed unique expression signatures. 
 
Existing mouse models for AIP rely on inducing pancreatitis via experimental means i.e. by 
immunization with self-antigens, injection of pathogens [35] or via adoptive transfer of auto-
reactive cells or Tregs [36-38]. However, such models can be highly variable. Even though 
spontaneous AIP development has been reported previously in genetic backgrounds prone 
to develop autoimmunity [39], a genetic model of AIP with robust penetrance and phenotypic 
reproducibility on C57BL/6 background did not exist.  
 
Based on our data derived from human AIP patients we have established a novel transgenic 
mouse model of AIP by expressing LTαβ specifically on acinar cells. This led to a 
transcription profile of inflammatory chemokines and cytokines reminiscent of human AIP, 
causally linking LT expression in the pancreas to AIP development. Ectopic LT expression 
induced the generation of TLTs - as frequently found in AIP. Surprisingly, localized 
inflammation in the pancreas developed into AIP and systemic autoimmune disease over 
time. This coincided with a rise in endogenous pancreatic LTαβ transcripts, most likely 
produced by infiltrating immune cells making the inflammatory reaction in the pancreas self-
sustaining.  
 
AIP in Tg mice was characterized by (1) development of antibodies against pancreatic self-
antigens, (2) presence of ANA, (3) rise in serum IgG, (4) antibodies against commensal 
bacteria and (5) extrapancreatic manifestation. Formation of pancreatic TLTs, T-cell 
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polarization (mainly towards Th1), systemic autoimmunity and other organ involvement (e.g. 
kidney) in Tg mice suggests a disease profile consistent with Type 1 human AIP. The degree 
of LTαβ transcript up-regulation in transgenic pancreata (50-500x) was comparable to 
pancreata of human AIP patients (100-200x). 
 
Flow cytometry analysis demonstrated a strong shift in the activation of pancreatic effector 
and memory T-cells in Tg(ELa1-Lta,b) mice. As in other autoimmune diseases, a local 
increase in Treg cells was observed [40] [26] [41] [42]. TNF has the capacity to expand the 
functional Tregs, representing a negative feedback loop to counteract TNF-induced pro-
inflammatory effects [43]. This implies that the significantly elevated TNF in 12-month-old 
transgenic mice correlates with the increase in Treg subset. However, decreased functionality 
of Tregs, or Teff resistance on Treg-mediated suppression has been described in human 
autoimmune diseases [44], which could contribute to AIP development in Tg(ELa1-
Lta,b)mice.  
 
In Tg(ELa1-Lta,b) mice nuclear translocation of RelB was observed, while RelA subunit 
remained cytoplasmic. This underlines the relevance of non-canonical NF-κB signaling in the 
pathogenesis of AIP in Tg(ELa1-Lta,b) mice. Furthermore, AIP in Tg(ELa1-Lta,b) mice 
coincided with activation of Stat3 signaling in acinar and inflammatory cells. 
 
The autoimmune phenotype in Tg(ELa1-Lta,b) mice could be prevented by genetic depletion 
of lymphocytes. In contrast, absence of pro-inflammatory (Ly-6Chi) monocytes identifies them 
as important contributors to early acinar cell damage. However, lack of Ly6Chi monocytes did 
not ablate development of autoimmunity, in contrast to autoimmune models of the CNS [32]. 
Adoptive transfer of transgenic splenocytes into Rag1-/- recipients resulted in influx of T-cells, 
but not B-cells in pancreata in parallel with acute pancreatic damage. These data suggest 
that in contrast to the early pancreatic damage mediated by innate immune cells (e.g. pro-
inflammatory monocytes), subsequent damage in Tg(ELa1-Lta,b) mice is influenced by 
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adaptive immunecells , particularly T-cells. This is corroborated by the strong reduction of 
pancreatic tissue damage (e.g. serum lipase) in Tg(ELa1-Lta,b)xRag1-/- mice between 6-12 
months of age. In contrast, Tg(ELa1-Lta,b)xCCR2-/- mice display similar pancreatic tissue 
damage when compared to Tg(ELa1-Lta,b) mice. 
 
Thus, acinar-cell specific expression of LT leads to two independent reactions: (1) Early 
onset of pancreatitis, attracting innate immune cells (e.g. pro-inflammatory monocytes) and 
activating tissue macrophages, presumably to remove non-viable pancreatic cells. (2) 
Recruitment of lymphocytes to the pancreas results in further increase in cytokine and 
chemokine expression contributing to an inflammatory milieu sustaining pancreatitis, 
metaplasia and enabling germinal center and TLT formation. This environment fosters 
activation, clonal selection and expansion of auto-reactive lymphocytes in Tg(ELa1-
Lta,b)mice. 
 
Currently, the treatment options for AIP are limited. AIP patients respond well to 
corticosteroid treatment; however disease relapses are frequent. Interestingly, neither pro-
inflammatory cytokines nor homeostatic chemokines were reduced upon steroid treatment in 
sera of human AIP patients, which is likely responsible for the disease relapse. Therefore, a 
complementary treatment that could additionally down-regulate inflammatory mediators is 
likely to benefit patients. 
 
Corticosteroid treatment of Tg(ELa1-Lta,b) mice reduced pancreatic inflammation, yet failed 
to revert the autoimmune repertoire (e.g. anti-PSTI antibodies). In contrast, treatment with 
LTβR-Ig led to strong decrease of inflammation and also ablated AIP in Tg mice. We also 
depleted germinal center B-cells using anti-CD40L antibody [45]. Although IgG levels were 
reduced, the load of pancreatic inflammation and progression to AIP remained unchanged in 
Tg(ELa1-Lta,b) mice. This could possibly be explained by the presence of long-lived plasma 
cells in the pancreas that do not respond to anti-CD40L treatment.  
17 
 
 
While corticosteroid treatment was anti-inflammatory, LTβR-Ig treatment had additional anti-
autoimmune effects. Suppression of LTβR-signaling in mice with established AIP protects 
against peripheral AIP pathologies. Therefore, inhibition of LTβR-signaling pathway could be 
a viable alternative or supplementary approach for AIP treatment. 
 
In summary, increased local LT expression in the pancreas is sufficient to to reproduce 
various clinical features of human AIP and to induce systemic autoimmunity. Tg(ELa1-Lta,b) 
mice will facilitate the study of AIP pathogenesis and allow testing potential treatment 
interventions. 
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Figure legends: 
 
Figure 1: Characterization of human autoimmune pancreatitis and non-autoimmune 
pancreatic inflammatory diseases. (A) Histological analysis of representative human 
pancreatic tissues from healthy controls (n=6) (scale bar: 100μm), patients with chronic 
pancreatitis, severe fibrosis and ductal precipitates (asterisk) (n=12) (scale bar: 200μm) and 
patients with AIP and vasculitis (arrows; n=16) (scale bar: 100μm). H/E staining shows 
typical features of pancreatic inflammation (fibrosis) and autoimmune disease (inflammatory 
infiltrates, vasculitis). (B) qPCR analysis of human cryo-material from pancreatic tissues 
(control n=6, non AIP n=6, AIP n=5) for LTa and LTb transcripts, homeostatic chemokines 
and LT target genes (e.g. CXCL13, CCL19, CCL21, CCL17, CCL20) as well as inflammatory 
mediators (BAFF, TNFα , CCL2, IL6, IL17). (C) Immunohistochemical analysis indicates 
human LTβ expression on inflammatory and acinar cells - especially those undergoing 
acinar-ductal metaplasia (ADM) (insets). Scale bars: Upper row: Control: 200μm. Severe 
fibrosis and AIP: 100μm. Lower row: 50μm. (D) Serum from healthy controls (n=12) and AIP 
patients (n=10) - before and after corticosteroid treatment – was analysed for protein 
expression of CXCL13, CCL19, TNFα   and IL6; One-way ANOVA (Kruskal Wallis test with 
Dunn’s Multiple Comparison Post test).*: P<0.05; **: P<0.01, ***: P<0.001. 
 
Figure 2: Description of pancreatitis in Tg(Ela1-Lta,b) mice. (A) Serum lipase and 
amylase levels are elevated in Tg(ELa1-Lta,b) mice compared to wild type (n=4-7). Changes 
in pancreas size are visualized by pancreas-to-body-weight ratio with significant decrease in 
transgenic mice (n=4) compared to wild type (n=5) (P=0.0001, P=0.0028, P=0.0049); 
Unpaired t-test. (B) Development and progression of pancreatic inflammation visualized by 
H/E staining from 3, 6, 12, 18 and 22 month-old Tg(ELa1-Lta,b) mice compared to age 
matched negative littermates (scale bar: 100 μm). (C) Typical features of chronic pancreatitis 
were found in Tg(ELa1-Lta,b) mice: ADM (scale bar: 20μm), goblet cell metaplasia (Scale 
bar: 50μm) and vasculitis (scale bar: 100μm). *: P<0.05; **: P<0.01, ***: P<0.001. 
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Figure 3: Cellular and molecular characterization of Tg(ELa1-Lta,b) mice. (A) qPCR 
analysis of pancreatic Lta, Ltb, Cxcl13, Ccl19, Ccl21, Ccl17, Ccl20, Vcam, Cxcl1, Cxcl10, 
Ccl2, Il6, Il1β, Baff (Tnfsf13b), Il7 and Tnfα transcripts in 3 and 12 month-old Tg(ELa1-Lta,b) 
pancreata compared to negative littermates (3 and 12 months). (B) Elisa for CXCL13, 
CXCL10, CXCL1, IL6 and IL1β in pancreas homogenates of C57BL/6 andTg(ELa1-Lta,b) 
mice. (C) Serum CXCL13 levels are elevated in 12 month-old Tg(ELa1-Lta,b) (n=10) mice 
compared to age matched C57BL/6 (n=10) mice. (D) Quantification of CD4+, CD8+, B220+ 
and CD11b+ infiltrating cells at the age of 3 and 6 months in transgenic and wild type 
mice.(E) Intraperitoneal glucose tolerance test (IP-GTT) of 12 month-old Tg(ELa1-Lta,b) and 
C57BL/6N mice shows no signs of diabetes in Tg(ELa1-Lta,b) mice, however plasma insulin 
levels are significantly higher throughout IP-GTT. *: P<0.05; **: P<0.01, ***: P<0.001. 
 
Figure 4: Flow cytomerty and immunohistochemical analysis of chronically inflamed 
Tg(ELa1-Lta,b) pancreata. (A) Flow cytometry analysis for activated CD4+, CD8+ T-cells (B) 
regulatory T-cells (FoxP3+CD4+) in pancreata and mesenteric lymph nodes (mLN) of 12 
month-old Tg(ELa1-Lta,b) and C57BL/6 mice. (C) Quantification of activated CD4+, CD8+ T-
cells and regulatory T-cells in pancreata and mLNs; unpaired t-test from 3 independent 
experiments. (D) qPCR analysis of pancreatic Tnfα , Ifnγ , T-bet, Gata3, Il4 and Il10 
transcripts in 3 (n=5) and 6 month-old (n=5) Tg(ELa1-Lta,b) pancreata compared to negative 
littermates (n=5) (3 and 6 months); one-way ANOVA (Kruskal Wallis test with Dunn’s Multiple 
Comparison Post test). (E) Between 3 and 12 months of age Tg(ELa1-Lta,b) mice develop 
high endothelial venules (HeV), which are absent from pancreata of age matched C57BL/6 
mice (PNAd staining) (scale bar: 100μm). (F) After 6 months of age inflammatory infiltrates 
are found with distinct CD3+ and B220+ T- and B-cell zones (scale bar: 200μm). The cluster 
of Ki67+ proliferating inflammatory cells (scale bar: 200μm) is indicative of a germinal center, 
which is supported by the presence of CD21/35+ germinal center B-cells (scale bar: 100μm) 
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and follicular dendritic cell networks (FDC-M1+) (scale bar: 100μm). *: P<0.05; **: P<0.01, 
***: P<0.001. 
 
Figure 5: Detection of antinuclear antibodies (ANA), auto-antibodies against pancreas-
specific proteins and immune complex glomerulonephritis. (A) Serum analysis of 12 
month-old Tg(ELa1-Lta,b) shows significantly elevated total IgG, IgG1, IgG2b, IgM and IgA  
levels compared to negative littermates. (B) Detection of antinuclear-antibodies (ANA) on 
Hep2 cells with sera obtained from 6, 12 and 18 month-old C57BL/6 and Tg(ELa1-Lta,b) 
mice (scale bar: 20μm). (C) Transgenic mice possess elevated serum anti-nucleosome, anti-
dsDNA antibodies. Rheumatic factor and anti-Smith IgG levels are indicative of a systemic 
autoimmune disease. (D) Detection of anti-PSTI, anti-lactoferrin and anti-lipase antibodies in 
sera from 12 month-old Tg(ELa1-Lta,b) and C57BL/6 mice. (E) Representative 
immunohistochemistry from Rag1-/-pancreata after spleen-cell transfer from 12 month-old 
Tg(ELa1-Lta,b) and C57BL/6 mice (n=3 each). Presence of CD3+ T-cells in Rag1-/-tissue 
indicates that autoimmune disease is transferable (scale bars from left to right: 100μm, 
200μm, 200μm). Transferred spleen-cells from Tg(ELa1-Lta,b) mice led to pancreatic tissue 
damage in Rag1-/-mice shown by elevated amylase levels. Unpaired t-test was used to 
compare wild type to transgenic mice. (F) Prominent IgG deposits (arrow) in the mesangium 
of Tg(ELa1-Lta,b) kidneys compared to controls in which only intravascular IgG is stained. 
Quantification of IgG deposits in the mesangium and macrophage accumulation in capillaries 
in 3, 6, 12, 15 and 18 months old Tg(ELa1-Lta,b) (n=5) compared to a pool (n=8) of 
representative age groups from C57BL/6 mice; unpaired t-test. *: P<0.05; **: P<0.01, ***: 
P<0.001. 
 
Figure 6: CCR2+ macrophages aggravate the initiation phase of chronic pancreatitis 
whereas lymphocytes contribute to late damage and autoimmunity. (A) 
Immunohistochemical characterization of   2 and 12-month-old Tg(ELa1-Lta,b)xRag1-/- and 
Tg(ELa1-Lta,b)xCcr2-/- mice. H/E, F4/80+ macrophages, Ki67+ proliferating inflammatory and 
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acinar cells, CD3+ T-cells and B220+ B-cells are indicated (scale bar: 200μm). (B) Serum 
lipase levels  of 1, 3, 6 and 12 month-old C57BL/6 (n=9); Tg(ELa1-Lta,b) (n=10); Tg(ELa1-
Lta,b)xRag1-/-(n=6), Tg(ELa1-Lta,b)xCcr2-/-(n=4) mice;  unpaired t-test to compare wild type 
to Tg(Ela1-LTa,b) mice; One-way ANOVA (Kruskal Wallis test with Dunn’s Multiple 
Comparison Post test) for comparing Tg(ELa1-Lta,b)xRag1-/-and Tg(ELa1-Lta,b)xCcr2-/-
groups to Tg(ELa1-Lta,b) group  . (C) qPCR results from 8 week-old mice (n=4 each) show 
differences of chemokine and cytokine transcripts (CXCL13, CCL19, CCL21, CXCL1, 
CXCL9, CXCL10) and genes involved in macrophage activation (TNFα, MCP-1, IL-6, F4/80);    
One-way ANOVA (Kruskal Wallis test with Dunn’s Multiple Comparison Post test). (D) IgG 
deposits in kidneys from mice of various genotypes illustrates prominent IgG1 deposits in 
Tg(ELa1-Lta,b)xCCR2-/- mice. (Scale bar 50μm). *: P<0.05; **: P<0.01, ***: P<0.001. 
 
 
Figure 7: Response to prednisolone or LTβR-Ig treatment in established AIP of 
Tg(ELa1-Lta,b) mice. (A) Immunohistochemical characterization of pancreatic tissue from 
12 month-old mice treated with prednisolone for 4 weeks and with LTβR-Ig fusion protein , 
compared to age matched untreated Tg(ELa1-Lta,b) mice  (scale bar: 200μm). H/E, CD3+ T-
cells, B220+ B-cells, Ki67+ proliferating inflammatory cells and acinar cells and F4/80+ 
macrophages are indicated (scale bar: 200μm). (B) Both prednisolone and LTβR-Ig 
treatment reduces ADM. H/E staining of 12 months old Tg(ELa1-Lta,b) mice untreated (n=5), 
treated with prednisolone (n=5) and LTβR-Ig (n=5). (scale bar:100μm). ADM was quantified 
and normalized to mm2 of pancreatic tissue including control IgG treatment group (n=5). (C) 
Detection of CXCL10 and CXCL13 protein expression in pancreata of treated (n=5) and 
control mice (n=3). (D) Detection of anti-PSTI antibodies in untreated Tg(ELa1-Lta,b) mice 
(n=15) and after treatment with either prednisolone (n=3) or LTβR-Ig (n=4) compared to 
controls (n=6). (E) Quantification of IgG1 deposits in glomeruli treated with prednisolone 
(n=3) or LTβR-Ig (n=4) compared to untreated Tg(ELa1-Lta,b) (n=8) and C57BL/6 (n=8) 
23 
 
animals; unpaired t-test. (F) Representative images of IgG deposits in kidneys after LTβR-Ig 
and prednisolone treatment. Scale bar: 50μm.*: P<0.05; **: P<0.01, ***: P<0.001.¨ 
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